 |
 |
 |
Top News
 |
Ofatumumab promising in refractory follicular lymphoma Jul 22, 2008 NEW YORK (Reuters Health) - The human monoclonal antibody ofatumumab was well tolerated by patients with relapsed or refractory follicular non-Hodgkin's lymphoma in a Phase 1 / 2 safety and efficacy trial, according to European researchers. |
 |
U.S. FDA, CDC say Merck's Gardasil shot remains safe Jul 22, 2008 WASHINGTON (Reuters) - A review of health problems reported after women and girls received Merck & Co's Gardasil vaccine shows it remains safe and effective for protecting against a virus that causes cervical cancer, U.S. officials said on Tuesday. |
 |
Possible biomarkers for critical limb ischemia identified Jul 22, 2008 NEW YORK (Reuters Health) - In patients with peripheral arterial disease, levels of vascular endothelial growth factor (VEGF) and soluble Tie2 (sTie2) are increased when critical limb ischemia rather than intermittent claudication is present, new research suggests. |
 |
Quest profit beats expectations, shares rise Jul 22, 2008 NEW YORK (Reuters) - Quest Diagnostics Inc, the largest U.S. medical testing company, Tuesday posted better-than-expected quarterly profit, helped by its acquisition of rival Ameripath. |
 |
Forest Labs quarterly profit beats estimates Jul 22, 2008 NEW YORK (Reuters) - Forest Laboratories Inc reported a 9 percent decline in quarterly profit on Tuesday on higher sales and administrative costs, but results were better than expected and the company forecast fiscal-year earnings ahead of analyst projections. |
 |
Czech PPF withdraws Zentiva bid, Sanofi alone Jul 22, 2008 PRAGUE (Reuters) - Czech financial group PPF gave up the race to take over generic drugs maker Zentiva on Tuesday, clearing the field for shareholders to weigh the merits of a competing bid from Sanofi-Aventis of France. |
 |
Analysts cut Merck target on withheld view; shares fall Jul 22, 2008 BANGALORE (Reuters) - Leerink Swann downgraded Merck & Co Inc, while several other brokerages cut their targets on the stock Tuesday, a day after the drug maker withheld its 2008 earnings forecast after a mostly negative study on cholestrol treatment Vytorin, sending its shares down to their lowest in 2-½ years. |
 |
Biogen profit up 11 pct, Tysabri shines Jul 22, 2008 NEW YORK (Reuters) - Biogen Idec Inc reported a higher-than-expected second-quarter profit on Tuesday as sales of its closely watched multiple sclerosis drug Tysabri surged past Wall Street estimates, pushing its shares up more than 5 percent. |
 |
U.S. regulators reviewing latest Vytorin heart data Jul 22, 2008 WASHINGTON (Reuters) - U.S. drug regulators said on Monday they are reviewing the latest data that found Schering-Plough Corp and Merck & Co Inc's drug Vytorin failed to improve heart outcomes in a widely-watched clinical study. |
 |
Amylin posts wider second-quarter net loss Jul 22, 2008 LOS ANGELES (Reuters) - Amylin Pharmaceuticals Inc reported a wider quarterly loss Monday due to increased expenses as it works to develop a once-weekly diabetes treatment. |
 |
Endostatin levels reflect pancreatic cancer progression Jul 22, 2008 NEW YORK (Reuters Health) - Endostatin levels are increased in patients with pancreatic cancer and decline after surgical treatment or chemotherapy, according to a report in the June 15th International Journal of Cancer. |
|
 |
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
|  |
|
|
|
 |
| |